Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib.
about
Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Reply: Costs of managing adver ...... n-α2a compared with sunitinib.
@en
Reply: Costs of managing adver ...... n-α2a compared with sunitinib.
@nl
type
label
Reply: Costs of managing adver ...... n-α2a compared with sunitinib.
@en
Reply: Costs of managing adver ...... n-α2a compared with sunitinib.
@nl
prefLabel
Reply: Costs of managing adver ...... n-α2a compared with sunitinib.
@en
Reply: Costs of managing adver ...... n-α2a compared with sunitinib.
@nl
P2093
P2860
P356
P1476
Reply: Costs of managing adver ...... ron-2a compared with sunitinib
@en
P2093
B Escudier
G H J Mickisch
P2860
P304
P356
10.1038/SJ.BJC.6605887
P407
P577
2010-10-12T00:00:00Z